Clinical Research

South Coast Renal operates a Clinical Research Facility (CRF) located on the ground floor of Brockway House. This modern facility offers cutting-edge resources and expertise for both investigator-led and commercially sponsored clinical trials. The highly experienced clinical trials team manages and coordinates research across multiple phases.

The CRF includes a welcoming reception and waiting area, clinical spaces such as a phlebotomy room, a transfusion room, three interview rooms, and a dedicated clinical area. The clinical area is equipped for processing trial samples, with temperature-controlled fridge/freezer storage for samples and medications.

CURRENT ACTIVE STUDIES:

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure (BaxDuo-Pacific)

Brief Summary
International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenously Administered PYC-003, a Peptide-phosphorodiamidate Morpholino Oligonucleotide Conjugate, in Healthy Adult Participants and Adult Participants With Confirmed PKD1 Mutation-associated Autosomal Dominant Polycystic Kidney Disease

Brief Summary

This is a first-in-human multi-centre Phase 1a and Phase 1b, single ascending dose (SAD) interventional study of PYC-003 in healthy volunteers and patients with confirmed PKD1 mutation-associated Autosomal Dominant Polycystic Kidney Disease.

A Phase 2 Study to Evaluate the Safety and Efficacy of Atacicept in Multiple Autoimmune Glomerular Diseases (PIONEER)

Brief Summary

To evaluate the efficacy and safety of atacicept in a wider range of autoimmune kidney diseases.
Drug: Atacicept, a fusion protein that blocks B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL) to reduce autoantibodies.

Conditions: The study includes patients with:
Expanded IgA Nephropathy (IgAN) populations: Including those with lower kidney function or high/low proteinuria. Anti-PLA2R podocytopathies (pMN) .Focal segmental glomerulosclerosis (FSGS): and minimal change disease (MCD). IgA Vasculitis Nephritis .

Key benefits of utilising the CRF at South Coast Renal include:

  • A patient-centered environment focused on comfort
  • Spacious, well-lit rooms designed for a calming experience
  • On-site specialist nursing staff to care for patients
  • Temperature-controlled storage for Investigational Products (IP) and lab samples
  • Strict adherence to national and international clinical trial standards
  • Efficient implementation planning to ensure smooth trial completion.